SAHPRA has reportedly stopped approving new Section 21 applications for medical cannabis since July 2026, without explaining the decision. While the provision was intended for patients needing unregistered medicines, the cannabis industry allegedly exploited it as a retail loophole. However, legitimate patients, pharmacies and manufacturers say the halt is disrupting essential treatment, including for severe epilepsy. Stakeholders argue that abruptly ending approvals without an alternative pathway threatens continuity of care. The controversy highlights South Africa’s broader regulatory uncertainty around cannabis. Industry representatives are calling for clear registration procedures, stronger oversight and a workable legal framework for medical cannabis products. – MedicalBrief (4 Nov 2026)
[BACK TO NEWS]